구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD30+ CAR T-cells |
Overview Company | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Classical Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results |
MoA Biomarker | CD19 CAR T-cells produce high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30 + lymphomas.. INTRODUCTION: Although CD30-directed chimeric antigen receptor (CAR)-T cell therapy has demonstrated antitumor activity in CD30+ lymphomas, its therapeutic efficacy remains suboptimal. We therefore conducted a prospective, phase II, single-arm, multicenter clinical trial (ChiCTR-2100046763) to eva… |
Toxicology CRS | Reported |
Clinical Safety signal | CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30 + lymphomas.. INTRODUCTION: Although CD30-directed chimeric antigen receptor (CAR)-T cell therapy has demonstrated antitumor activity in CD30+ lymphomas, its therapeutic efficacy remains suboptimal. We therefore conducted a prospective, phase II, single-arm, multicenter clinical trial (ChiCTR-2100046763) to eva… |
Clinical Result source | ClinicalTrials.gov NCT03049449 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03049449 |
Preclinical Animal (cat.) | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD30+ CAR T-cells |
Overview Company | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Classical Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results |
MoA Biomarker | CD19 CAR T-cells produce high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30 + lymphomas.. INTRODUCTION: Although CD30-directed chimeric antigen receptor (CAR)-T cell therapy has demonstrated antitumor activity in CD30+ lymphomas, its therapeutic efficacy remains suboptimal. We therefore conducted a prospective, phase II, single-arm, multicenter clinical trial (ChiCTR-2100046763) to eva… |
Toxicology CRS | Reported |
Clinical Safety signal | CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30 + lymphomas.. INTRODUCTION: Although CD30-directed chimeric antigen receptor (CAR)-T cell therapy has demonstrated antitumor activity in CD30+ lymphomas, its therapeutic efficacy remains suboptimal. We therefore conducted a prospective, phase II, single-arm, multicenter clinical trial (ChiCTR-2100046763) to eva… |
Clinical Result source | ClinicalTrials.gov NCT03049449 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03049449 |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교